Evinacumab-dgnb Injection - Uses, Dosage, Precautions, and Mechanism of Action

What Is Evinacumab-dgnb Injection?

Evinacumab is a medicine that helps people with very high bad cholesterol, especially those with a rare condition called homozygous familial hypercholesterolemia. Bad cholesterol, or LDL, can build up in the blood and hurt the heart. Evinacumab works by blocking ANGPTL3 (angiopoietin-like protein 3), which usually slows the body’s ability to break down fats. By blocking it, the medicine helps the body remove more bad cholesterol. Doctors tested it in large studies, and in February 2021, the FDA (Food and Drug Administration) approved it for people with this rare condition to keep their hearts healthier.

Dosage Forms and Strengths

Evinacumab-dgnb injection is given at a recommended dose of 15 mg per kg body weight as an intravenous (IV) infusion once every 4 weeks, with each dose administered slowly over approximately 60 minutes. The exact dose is calculated by the doctor based on the patient’s current weight. It is available as a sterile liquid solution for injection in single-dose vials, with each vial containing 345 mg of Evinacumab-dgnb in 2.3 mL for intravenous use.

What Are the Uses of Evinacumab-dgnb?

Evinacumab is a monoclonal antibody medicine that helps lower bad cholesterol (LDL) in the blood. It is used alongside other cholesterol-lowering medicines for children aged 12 and older and adults with a rare genetic condition that causes very high LDL cholesterol.

For Patients

Understanding Cholesterol and Homozygous Familial Hypercholesterolemia

Cholesterol is a type of fat produced by our bodies. We need a little cholesterol to stay healthy. It helps make vitamins and hormones.

Cholesterol moves in our blood in two ways:

• Bad cholesterol (LDL) can stick inside blood tubes and make them narrow.

• Good cholesterol (HDL) helps clean extra cholesterol and keeps the blood tubes clear.

Bad cholesterol can clog blood vessels, just like dirt in a pipe, and this can stop blood from reaching the heart or brain. Homozygous familial hypercholesterolemia (HoFH) is a rare problem that children are born with. It means they have very high levels of bad cholesterol, which can harm the heart early in life. That is why it needs early treatment.

Why Is Evinacumab-dgnb Prescribed?

Evinacumab-dgnb is a medicine used with other treatments to lower “bad” cholesterol (LDL) and other fats in the blood. It is especially for people with homozygous familial hypercholesterolemia, a rare inherited condition in which the body cannot properly remove bad cholesterol, leading to very high cholesterol levels.

Evinacumab-dgnb belongs to a group called angiopoietin-like protein 3 inhibitor antibodies, which are medicines that target a specific protein in the body to help reduce cholesterol.

Too much cholesterol can build up on the walls of blood vessels (called plaque), making it harder for blood to flow to the heart, brain, and other parts of the body. By lowering cholesterol, Evinacumab-dgnb helps prevent heart disease, strokes (which happen when blood cannot reach part of the brain), and heart attacks.

How Should Evinacumab-dgnb Be Used?

• Evinacumab-dgnb is a liquid medicine given through a vein (intravenously).

• The infusion takes about 60 minutes and is usually done once every four weeks.

• A doctor monitors the patient closely during the infusion because serious reactions can occur.

• Discuss with the doctor immediately if you notice any of these symptoms:

  • Shortness of breath or wheezing.

  • Rash, hives, or itching.

  • Dizziness or nasal congestion.

  • Swelling of the face, throat, tongue, lips, or eyes.

  • Fever, nausea, or muscle weakness

• If side effects happen, the doctor may slow or stop the infusion. So, tell your doctor about any symptoms right away.

What Special Precautions Should Be Taken?

• Allergies: Tell your doctor if you have any allergy to Evinacumab, any other medicines, or any ingredients in the medication.

• Current Medications: Tell your doctor about all prescription and non-prescription drugs, vitamins, supplements, or herbal products you are taking or plan to take.

• Pregnancy and Breastfeeding:

  • Tell your doctor if you are pregnant or plan to get pregnant.

  • A pregnancy test is usually recommended before starting treatment.

  • Use effective birth control during treatment and for five months after the last dose.

  • If you become pregnant while on Evinacumab-dgnb, inform your doctor immediately.

What Special Dietary Instructions Should Be Followed?

• Eat a low-fat and low-cholesterol diet.

• Follow all diet and exercise advice given by your doctor.

What Are the Side Effects of Evinacumab-dgnb?

• Runny nose.

• Nasal congestion.

• Sore throat.

• Flu-like symptoms.

• Nausea.

• Dizziness.

• Pain in arms or legs.

• Low energy or fatigue.

Overdose

If an overdose happens, call the poison control helpline at once. Get emergency help right away if the person collapses, has seizures, cannot breathe properly, or cannot wake up.

Other Information

• Keep a written list of all medicines, including prescription drugs, over-the-counter medicines, vitamins, and herbal or dietary supplements.

• Bring this list to every doctor’s visit.

• Carry the list in case of emergencies so healthcare providers know what you are taking.

Storage and Disposal

• Store unopened Evinacumab-dgnb in the refrigerator at 36 to 46°F (2 to 8 °C) and use within 24 hours of preparation.

• The diluted solution can be kept at room temperature up to 77°F (25°C) for six hours.

• Use the diluted solution fresh and immediately after preparation.

• Discard any leftover medicine in the vial.

For Doctors

How Is Evinacumab-dgnb Prepared and Given?

• Calculate Dose and Volume: Determine the correct dosage, total volume, and number of vials based on the patient’s current body weight.

• Inspect the Solution: Before use, visually check the medicine for any discoloration, cloudiness, or particles. Evinacumab-dgnb should appear clear to slightly opalescent and colorless to pale yellow. Do not use it if it looks discolored, cloudy, or contains particles.

• Handling: Do not shake the vial. Withdraw the required amount and transfer it to an IV infusion bag containing up to 250 mL of 0.9% Sodium chloride or 5% Dextrose solution. Mix gently without shaking.

• Final Concentration: The diluted solution should be between 0.5 mg/mL and 20 mg/mL, depending on the patient’s weight.

Administration Instructions for IV Infusion

• If refrigerated, allow the solution to come to room temperature before use.

• Administer the diluted Evinacumab-dgnb through an IV line with a sterile 0.2 to 5 micron filter over 60 minutes.

• Do not mix Evinacumab-dgnb with other medications or give it through the same infusion line as other drugs.

• The medication can be given regardless of the timing of lipoprotein apheresis (a procedure to remove cholesterol from the blood).

What Are the Pharmacological Aspects of Evinacumab-dgnb?

1. How Evinacumab-dgnb Works (Mechanism of Action):

Evinacumab-dgnb is a monoclonal antibody, meaning it targets a specific protein in the body. It works by blocking angiopoietin-like protein 3 (ANGPTL3), a protein mainly produced in the liver that helps regulate blood lipid levels, including cholesterol and triglycerides.

Under normal conditions, ANGPTL3 slows down enzymes that break down fats in the blood. When Evinacumab-dgnb blocks this protein, these enzymes work more effectively, helping the body clear excess cholesterol and triglycerides from the blood.

This mechanism is particularly useful for people with homozygous familial hypercholesterolemia, a rare genetic condition in which the body cannot properly remove LDL (“bad”) cholesterol.

By inhibiting ANGPTL3, Evinacumab-dgnb lowers levels of LDL cholesterol, HDL cholesterol (“good” cholesterol), and triglycerides, reducing the buildup of plaque in blood vessels, which can otherwise lead to heart attacks or strokes.

ANGPTL3 has only recently been targeted for cholesterol-lowering therapy, making Evinacumab-dgnb the first medicine in its class to act this way.

2. Effects on the Body (Pharmacodynamics):

Evinacumab-dgnb has several important effects on the body:

• It reduces LDL cholesterol, which is the primary contributor to plaque buildup in arteries.

• It lowers HDL cholesterol and triglycerides, helping to balance overall blood fat levels.

• It decreases apolipoprotein B and total cholesterol, both of which are markers of cardiovascular risk.

• By lowering these blood fats, the drug has anti-atherogenic effects, helping prevent the formation of arterial plaque.

Because Evinacumab-dgnb remains active in the body for a long time, it only needs to be given once a month as an intravenous (IV) infusion, which slowly delivers the medicine directly into the bloodstream.

3. How the Body Handles the Drug (Pharmacokinetics):

• Absorption: When Evinacumab-dgnb is administered by IV infusion, it reaches a peak concentration of about 689 mg/L at the end of the infusion. Over time, the blood levels stabilize, with an average steady level of about 241 mg/L between doses.

• Distribution: Once in the bloodstream, the drug distributes throughout the body, with a volume of distribution of around 4.8 liters, which is relatively small, indicating it mostly stays in the blood.

• Metabolism: Evinacumab-dgnb is broken down into small proteins and amino acids that the body can safely use or eliminate.

• Elimination: The drug is primarily removed by cells taking it up and breaking it down in lysosomes, which are cellular compartments that digest proteins. Because the molecule is large, it is usually not removed by the kidneys unless there is a rare problem with kidney function.

• Half-life: The time it takes for the drug to reduce by half in the blood depends on its concentration. At higher concentrations, it is removed by a regular, non-saturable breakdown process.

At lower concentrations, it is removed via a target-mediated pathway that depends on the amount of ANGPTL3 in the blood. This dual mechanism helps maintain a long-lasting effect, allowing once-a-month dosing.

What Are the Associated Warnings and Precautions?

• Serious Allergic Reactions: In clinical trials, one patient receiving Evinacumab-dgnb experienced severe allergic reactions (anaphylaxis), whereas none occurred with placebo. Evinacumab-dgnb should not be used in patients with a known allergy to this medication. If symptoms of an allergic reaction-such as rash, swelling, or difficulty breathing- appear, the drug should be stopped immediately.

• Risk to Pregnancy (Embryo-Fetal Toxicity): Animal studies suggest that Evinacumab-dgnb can harm a developing fetus. In rabbits, even doses lower than those used in humans increased the risk of birth defects. Before starting treatment, a pregnancy test should be considered. Patients who could become pregnant are advised to use effective contraception during treatment and for at least five months after the last dose of Evinacumab-dgnb.

• Drug Interactions: It is not known if Evinacumab-dgnb interacts with other medicines. Patients should tell their doctor about all medicines they are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.

Use in Specific Population:

• Pregnancy: Studies in animals suggest this medicine may harm a baby during pregnancy. We do not have enough human data to fully assess the risk. The drug can pass from the mother to the baby.

• Lactation (Breastfeeding): It is not known how Evinacumab-dgnb affects a breastfeeding infant. The benefits of breastfeeding should be weighed against the mother’s need for the drug. Infants should be monitored for any effects.

• Pregnancy Test: A pregnancy test is recommended before starting Evinacumab-dgnb.

• Contraception: If you can get pregnant, use birth control while taking this medicine and for 5 months after the last dose.

• Pediatric Use: Evinacumab-dgnb is approved for children 12 years and older with homozygous familial hypercholesterolemia. Its safety and effectiveness in children under 12 are unknown.

• Elderly Patients: There is limited data on patients 65 years and older, so it is not clear whether older people respond differently from younger people.